UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its char ...

LivaNova PLC (NASDAQ:LIVN) Q2 2023 Earnings Conference Call July 26, 2023 8:00 AM ET Company Participants Matthew Dodds - SVP, Corporate Development & IT William Kozy - Chairman & Interim CEO Alex Shvartsburg - CFO Stephanie Bolton - President, Global Epilepsy Conference Call Participants Frederick Wise - Stifel, Nicolaus & Company Matthew Miksic - Barclays Bank Michael Polark - Wolfe Research Michael Matson - Needham & Company David Rescott - Robert W. Baird & Co. Matthew Taylor - Jefferies Adam Maeder - P ...

Kits used for cardiac procedures grew year over year, offset by respiratory case declines and product mix. | --- | --- | --- | --- | |---------------------------------------------------------------------|-------|---------|----------| | Adjusted Free Cash Flow Reconciliation ($M) 1Q 2023 | | 2Q 2023 | 2023 YTD | | Net cash provided by operating activities | $20.8 | $(17.9) | $2.8 | | Less: Purchases of plant, property and equipment (7.7) (5.7) (13.3) | | | | | Less: Cash received from tax stimulus (9.9) — (9 ...

LivaNova PLC (NASDAQ:LIVN) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President of Corporate Development William Kozy - Chairman & Interim Chief Executive Officer Alex Shvartsburg - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Financial Michael Polark - Wolfe Research Matthew Taylor - Jefferies Adam Maeder - Piper Sandler Mike Matson - Needham & Company Operator Good day ladies and gentlemen and welcome to the LivaNova ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its cha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its charter) England and Wales ................... 98-126815 ...

LivaNova PLC (NASDAQ:LIVN) Q4 2022 Results Earnings Conference Call February 22, 2023 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President, Corporate Development Damien McDonald - Chief Executive Officer Alex Shvartsburg - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Financial Michael Polark - Wolfe Research Matthew Taylor - Jefferies LLC Adam Maeder - Piper Sandler Mike Matson - Needham & Company, LLC Matt Miksic - Barclays Capital Operator Good day, ladies and g ...

Safe Harbor In this presentation, "LivaNova," "the Company," "we," "us" and "our" refer to LivaNova PLC and its consolidated subsidiaries. This report may contain references to our proprietary intellectual property, including among others: • Trademarks for our advanced circulatory support systems: TandemLife™, TandemHeart™, TandemLung™, ProtekDuo™, LifeSPARC™, ALung™, Hemolung™, Respiratory Dialysis™ and ActivMix™. Agenda Financial Results Financial Results 4Q22 Financial Summary Adjusted SG&A % 4Q21 4Q22 • ...

Liva\Nova | --- | --- | --- | --- | |--------------------------------|-------|-------|-------| | | | | | | Health innovation that matters | | | | Third Quarter 2022 Earnings Presentation November 2, 2022 Safe Harbor 2 Certain statements in this presentation, other than purely historical information, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as a ...

Financial Data and Key Metrics Changes - The company achieved a revenue growth of 5% in Q3 2022, with total revenue reaching $253 million compared to the previous year [9][28] - Adjusted gross margin was 70%, consistent with Q3 2021, but impacted by supply chain challenges and inflationary pressures [29] - Adjusted operating income decreased to $37 million from $46 million year-over-year, with an operating income margin of 15% down from 18% [31] - Adjusted diluted earnings per share were $0.58, down from $0.66 in Q3 2021 [33] - The company recorded a $129 million non-cash goodwill impairment charge for the ACS reporting unit [33] Segment Performance Changes - Cardiopulmonary segment revenue was $121 million, a 7% increase year-over-year, driven by high-single digit growth in oxygenator revenue [10][11] - Epilepsy revenue increased by 11%, with growth across all regions, primarily from replacement implants [12][13] - ACS revenue was $9 million, a significant decrease of 44% year-over-year, primarily due to a decline in severe COVID cases [17][21] Market Performance Changes - US epilepsy revenue grew 9% year-over-year, with total implants up mid-single digits [13] - The rest of the world region for epilepsy saw a 28% growth, led by Brazil [15] - The company expects global epilepsy revenue to grow 6% to 8% for the full year [16] Company Strategy and Industry Competition - The company is navigating macro headwinds including supply chain issues, inflation, and foreign exchange volatility [9] - Strategic portfolio initiatives include ongoing studies like the RECOVER study and ANTHEM-HFrEF trial, with expectations for continued progress [23][25] - The company plans to add two additional dedicated teams for epilepsy in Q4 to enhance market penetration [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about improving procedure trends globally, particularly in the US [47] - The company maintains its guidance for 2022, expecting constant currency revenue growth of 4% to 6% and adjusted EPS of $2.25 to $2.45 [36] - Management highlighted the potential impact of foreign exchange rates on future earnings, estimating a $0.35 EPS headwind [36][50] Other Important Information - The company’s cash balance at September 30 was $506 million, significantly up from $208 million at year-end 2021 [34] - Total debt increased to $540 million, primarily due to a $300 million term loan facility executed in July [34] - The FDA classified a field action related to the LifeSPARC controller as a Class I recall, but the device remains safe for use [20] Q&A Session Summary Question: Epilepsy performance drivers and backlog - Management noted improved market conditions and a backlog of approximately 300 patients remaining for EOS [42][44] Question: 2023 growth outlook - Management expects improving procedure trends but acknowledges ongoing macro challenges [47] Question: Essenz launch updates - The Essenz program is progressing well, with clinical cases expected before year-end in Europe [53] Question: ACS business confidence - Management indicated a modest improvement expected in Q4, with a focus on non-COVID cases [57] Question: RECOVER study interim analysis - Management remains confident in achieving statistical significance, even if the full 500 patients are required [60][81] Question: Retaining sales force amid ACS headwinds - Management has taken steps to retain the sales team and is optimistic about non-COVID business growth [65] Question: SG&A and R&D expense increases - The increase in expenses is attributed to the timing of spending, with lower expenses in the prior year due to pandemic impacts [67][68]